Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...

Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets ...

And if you’re going through this, you’re not alone – a poll by the National Sleep Foundation shows that 78 per cent of ...